Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent and follow the study schedule, including visits, treatments, and lab tests.
• People who have been clinically diagnosed with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment, or who still have detectable cancer at a very low level (or whose cancer has become detectable again at a very low level) after completing induction and consolidation therapy.
• People between the ages of 18 and 80 (inclusive).
• People whose general physical functioning falls within a certain range on a standard medical scale (ECOG score of 0–3, meaning anywhere from fully active to limited in self-care — confirm with trial site).
• People whose doctors estimate they have a life expectancy of more than 3 months from the time of signing consent.
• People whose haemoglobin (red blood cell) level is at or above a minimum threshold, including if that level is reached with the help of a blood transfusion.
• People whose kidneys, heart, lungs, and liver are functioning at or above certain minimum levels as determined by standard tests (confirm specific thresholds with trial site).
• People who are capable of becoming pregnant, or whose partners are capable of becoming pregnant, who agree to use effective contraception from before joining the study until at least 6 months after treatment ends, and who agree to notify the study team immediately if pregnancy occurs or is suspected.

Who may not be able to join:

• People who, within the past year, have had serious heart conditions such as severe heart failure, a heart attack, a procedure to open blocked heart arteries (angioplasty or stent), unstable chest pain (angina), or other significant symptomatic heart disease.
• People who currently have active graft-versus-host disease (a complication sometimes seen after stem cell transplants) or who need ongoing medication to suppress their immune system.
• People who have had another type of cancer within the past 5 years, with some exceptions for certain early-stage or fully treated skin cancers, cervical pre-cancers, localised prostate cancer after surgery, or early breast cancer after curative surgery (confirm with trial site).
• People who have an active infection requiring treatment with systemic medication, or who had an uncontrolled infection within the 7 days before screening (minor urinary or upper respiratory infections may be exceptions — confirm with trial site).
• People who test positive for certain infectious diseases, including active hepatitis B, active hepatitis C, HIV, or syphilis.
• People who have participated in another clinical trial within the past 4 weeks, or whose last dose of an experimental drug was less than 5 half-lives ago — whichever period is longer.
• People who have a history of severe allergic reactions to biological medicines (such as antibody-based therapies).
• People who have any unstable or serious ongoing illness affecting the liver, kidneys, or metabolism that requires medical treatment, as determined by the investigating doctor.
• People who are pregnant or breastfeeding, people who plan to become pregnant within 2 years after receiving the cell treatment, or male participants whose partners plan to become pregnant within 2 years after their cell treatment.
• People who have any other condition that the investigating doctor believes could increase risk or interfere with the study.

Important: Always verify eligibility with the trial site directly before applying.